January 3, 2018 / 11:38 AM / in 6 months

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

Jan 3 (Reuters) - Ardelyx Inc:

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

* ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO’S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​

* ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below